An experimental drug can slow progression of Alzheimer’s disease in those who start taking it when the disease is still in its early stages. Nature: The drug, a monoclonal antibody called donanemab, does not improve symptoms. But among people who started taking it at the earliest stages of Alzheimer’s, 47% had no disease progression on some measures after one year, compared with 29% who took a placebo. The drug does not provide as much benefit to people at later stages or those with a common genetic variation that raises the risk of the disease.
The results are “very encouraging,” says neurologist Reisa Sperling at Harvard Medical School in Boston, Massachusetts, particularly because they are similar to those of a similar drug called lecanemab. “It makes me feel we are on the right track.” Donanemab’s manufacturer Eli Lilly, based in Indianapolis, Indiana, presented the results of the 1,736-person trial today at the Alzheimer’s Association International Conference (AAIC) in Amsterdam, and published them1 in JAMA. The company released partial results in May, but researchers still had questions about the drug’s safety and efficacy in certain groups.<p><div class=“share_submission” style=“position:relative;”> <a class=“slashpop” href=“http://twitter.com/home?status=Alzheimer’s+Drug+Donanemab+Helps+Most+When+Taken+at+Earliest+Disease+Stage%2C+Study+Finds%3A+https%3A%2F%2Fscience.slashdot.org%2Fstory%2F23%2F07%2F18%2F1957252%2F%3Futm_source%3Dtwitter%26utm_medium%3Dtwitter”><img src=“https://a.fsdn.com/sd/twitter_icon_large.png”></a> <a class=“slashpop” href=“http://www.facebook.com/sharer.php?u=https%3A%2F%2Fscience.slashdot.org%2Fstory%2F23%2F07%2F18%2F1957252%2Falzheimers-drug-donanemab-helps-most-when-taken-at-earliest-disease-stage-study-finds%3Futm_source%3Dslashdot%26utm_medium%3Dfacebook”><img src=“https://a.fsdn.com/sd/facebook_icon_large.png”></a>
</div></p><p><a href=“https://science.slashdot.org/story/23/07/18/1957252/alzheimers-drug-donanemab-helps-most-when-taken-at-earliest-disease-stage-study-finds?utm_source=rss1.0moreanon&utm_medium=feed”>Read more of this story</a> at Slashdot.</p><iframe src=“https://slashdot.org/slashdot-it.pl?op=discuss&id=22980178&smallembed=1” style=“height: 300px; width: 100%; border: none;”></iframe>